Russell Investments Group
KPTI icon

Russell Investments Group’s Karyopharm Therapeutics KPTI Stock Holding History

Russell Investments Group’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.6K Buy
+1,592
New +$13.8K ﹤0.01% 3853
2024
Q1 		– Sell
-435
Closed -$5.64K – 3345
2023
Q4 		$5.64K Sell
435
-5,889
-93% -$79.4K ﹤0.01% 2896
2023
Q3 		$127K Sell
6,324
-40
-0.6% -$898 ﹤0.01% 2581
2023
Q2 		$171K Buy
6,364
+72
+1% +$3.1K ﹤0.01% 2503
2023
Q1 		$367K Sell
6,292
-3,452
-35% -$170K ﹤0.01% 2351
2022
Q4 		$497K Buy
9,744
+1,116
+13% +$77.4K ﹤0.01% 2289
2022
Q3 		$705K Buy
8,628
+1,355
+19% +$101K ﹤0.01% 2093
2022
Q2 		$491K Buy
7,273
+3,223
+80% +$296K ﹤0.01% 2278
2022
Q1 		$447K Buy
4,050
+4,003
+8,517% +$499K ﹤0.01% 2264
2021
Q4 		$4K Sell
47
-120
-72% -$12K ﹤0.01% 2984
2021
Q3 		$14K Sell
167
-3,344
-95% -$347K ﹤0.01% 3006
2021
Q2 		$542K Buy
3,511
+616
+21% +$89.4K ﹤0.01% 2565
2021
Q1 		$456K Sell
2,895
-834
-22% -$176K ﹤0.01% 2561
2020
Q4 		$864K Sell
3,729
-378
-9% -$87.6K ﹤0.01% 2179
2020
Q3 		$898K Buy
4,107
+2,190
+114% +$536K ﹤0.01% 2122
2020
Q2 		$543K Buy
+1,917
New +$567K ﹤0.01% 2355
2020
Q1 		– Sell
-1,107
Closed -$318K – 3089
2019
Q4 		$318K Buy
+1,107
New +$240K ﹤0.01% 2560
2018
Q3 		– Sell
-293
Closed -$75K – 2984
2018
Q2 		$75K Sell
293
-27
-8% -$6.68K ﹤0.01% 2768
2018
Q1 		$64K Hold
320
– – ﹤0.01% 2800
2017
Q4 		$47K Buy
+320
New +$51.4K ﹤0.01% 2873
2017
Q2 		– Sell
-4,992
Closed -$962K – 3000
2017
Q1 		$962K Buy
4,992
+2,544
+104% +$408K ﹤0.01% 2117
2016
Q4 		$343K Buy
+2,448
New +$331K ﹤0.01% 2579

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Russell Investments Group's KPTI Position: Q2 2026 in Review

Russell Investments Group opened a new position in Karyopharm Therapeutics (KPTI) in Q2 2026: 1,592 shares worth $15.6K. The stake represents ﹤0.01% of the portfolio and ranks #3853 among its holdings. This is a return to the name: Russell Investments Group previously reported a position in KPTI as recently as Q4 2023.

Russell Investments Group first reported a position in KPTI in Q4 2016 and has held it in 22 quarters since. The position peaked at $962K in Q1 2017. 96 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • Russell Investments Group held 1,592 shares of Karyopharm Therapeutics worth $15.6K as of Q2 2026.
  • Karyopharm Therapeutics was a new Russell Investments Group position in Q2 2026.
  • Karyopharm Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #3853 holding.
  • Russell Investments Group first reported a position in Karyopharm Therapeutics in Q4 2016 and has held it in 22 quarters since.
  • Russell Investments Group's Karyopharm Therapeutics position peaked at $962K in Q1 2017.
  • 96 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.